Nephros (OTCMKTS: NEPH) is one of 118 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Nephros to similar businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, dividends and risk.
Institutional and Insider Ownership
49.8% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 5.6% of Nephros shares are held by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Nephros and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Nephros and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nephros Competitors||$1.50 billion||$98.69 million||-154.90|
Nephros’ competitors have higher revenue and earnings than Nephros. Nephros is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and target prices for Nephros and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical & medical instruments” companies have a potential upside of 415.48%. Given Nephros’ competitors higher possible upside, analysts clearly believe Nephros has less favorable growth aspects than its competitors.
Volatility and Risk
Nephros has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Nephros’ competitors have a beta of 1.03, meaning that their average stock price is 3% more volatile than the S&P 500.
Nephros competitors beat Nephros on 8 of the 10 factors compared.
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.